US equities |
MU $878.84 ▼-5.63% NVDA $214.13 ▼-1.43% TSLA $354.72 ▼-2.13% AAPL $343.46 ▲+0.43% META $709.33 ▼-3.72% MSFT $529.05 ▼-1.93% SPCX $146.03 ▼-1.74% AMD $528.75 ▼-5.95%
FinancialContent

enGene Therapeutics Inc. - Common Stock (NQ:ENGN)

1.670 -0.040 (-2.34%)
Delayed Quote Updated: 4:00 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about enGene Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
enGene Reports Second Quarter 2025 Financial Results and Provides Business Update
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene Announces the Resignation of its Chief Medical Officer
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene to Present at the Jefferies Global Healthcare Conference
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene Names Amy Pott as Chief Global Commercialization Officer
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene to Participate in Upcoming Investor Conferences
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene Reports First Quarter 2025 Financial Results and Provides Business Update
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene to Participate in the Leerink Partners Global Healthcare Conference
From enGene Holdings Inc.
Via Business Wire
News headline image
This aTyr Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene Reports Full Year 2024 Financial Results and Provides a Business Update
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene to Participate in Upcoming Investor Conferences
From enGene Holdings Inc.
Via Business Wire
News headline image
This TechnipFMC Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
enGene to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
From enGene Holdings Inc.
Via Business Wire
News headline image
Why enGene Holdings Stock Is Trading Higher ↗
enGene shares are trading higher by 6.7% during Friday's session. The company announced it generated approximately $60 million in proceeds from a private placement. 
Via Benzinga
News headline image
enGene Announces $60 Million Private Placement Financing
From enGene Holdings Inc.
Via Business Wire
News headline image
IBM Posts Weak Sales, Joins Garrett Motion, Beyond And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From enGene Holdings Inc.
Via Business Wire
News headline image
Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene Reports Third Quarter 2024 Financial Results and Provides a Business Update
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene to Participate in Upcoming Investor Conferences
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene Announces Appointment of Ron Cooper as Chief Executive Officer
From enGene Holdings Inc.
Via Business Wire
News headline image
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
< Previous 1 2 3 4 Next >